EP1292279A4 - Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems - Google Patents

Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems

Info

Publication number
EP1292279A4
EP1292279A4 EP01941973A EP01941973A EP1292279A4 EP 1292279 A4 EP1292279 A4 EP 1292279A4 EP 01941973 A EP01941973 A EP 01941973A EP 01941973 A EP01941973 A EP 01941973A EP 1292279 A4 EP1292279 A4 EP 1292279A4
Authority
EP
European Patent Office
Prior art keywords
copolymer
treatment
nervous system
central nervous
system disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01941973A
Other languages
English (en)
French (fr)
Other versions
EP1292279A1 (de
Inventor
V Wee Yong
Sophie Chabot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1292279A1 publication Critical patent/EP1292279A1/de
Publication of EP1292279A4 publication Critical patent/EP1292279A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01941973A 2000-06-05 2001-06-05 Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems Withdrawn EP1292279A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58752300A 2000-06-05 2000-06-05
US587523 2000-06-05
PCT/US2001/018248 WO2001093828A1 (en) 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
EP1292279A1 EP1292279A1 (de) 2003-03-19
EP1292279A4 true EP1292279A4 (de) 2005-01-12

Family

ID=24350145

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01941973A Withdrawn EP1292279A4 (de) 2000-06-05 2001-06-05 Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems

Country Status (9)

Country Link
EP (1) EP1292279A4 (de)
JP (1) JP2003535118A (de)
AU (2) AU7528001A (de)
CA (1) CA2411536A1 (de)
HU (1) HUP0302333A3 (de)
IL (1) IL153236A0 (de)
PL (1) PL363431A1 (de)
WO (1) WO2001093828A1 (de)
ZA (1) ZA200210084B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
SI1797109T1 (sl) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
KR20170123354A (ko) 2009-08-20 2017-11-07 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2016029920A1 (en) 2014-08-29 2016-03-03 Aarhus Universitet Positively charged co-polymers for use as antimicrobial agents
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
US11058720B2 (en) 2016-05-20 2021-07-13 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031990A1 (en) * 1994-05-24 1995-11-30 Yeda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
WO2001052878A2 (en) * 2000-01-20 2001-07-26 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411292D0 (en) * 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
US5665764A (en) * 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031990A1 (en) * 1994-05-24 1995-11-30 Yeda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
WO2001052878A2 (en) * 2000-01-20 2001-07-26 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHARONI R ET AL: "COP 1 SPECIFIC SUPPRESSOR CELLS INHIBIT EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS INDUCED BY EITHER MOUSE SPINAL CORD HOMOGENATE ORPROTEOLIPID PROTEIN PEPTIDE 139-151", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 48, no. 3, SUPPL 2, 12 April 1997 (1997-04-12), pages A422, XP001029141, ISSN: 0028-3878 *
AHARONI R ET AL: "COPOLYMER 1 INDUCES T CELLS OF THE T HELPER TYPE 2 THAT CROSSREACT WITH MYELIN BASIC PROTEIN AND SUPPRESS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, September 1997 (1997-09-01), pages 10821 - 10826, XP002918836, ISSN: 0027-8424 *
See also references of WO0193828A1 *
TEVA ET AL: "COPOLYMER-1 GLATIRAMER ACETATE COPAXONE(R) AGENT FOR MULTIPLE SCLEROSIS", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 23, no. 2, 1998, pages 213 - 214, XP001029138, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
HUP0302333A3 (en) 2005-07-28
ZA200210084B (en) 2003-12-12
HUP0302333A2 (hu) 2003-11-28
CA2411536A1 (en) 2001-12-13
JP2003535118A (ja) 2003-11-25
WO2001093828A1 (en) 2001-12-13
PL363431A1 (en) 2004-11-15
IL153236A0 (en) 2003-07-06
AU7528001A (en) 2001-12-17
EP1292279A1 (de) 2003-03-19
AU2001275280B2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU7528001A (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
EP0924983A4 (de) S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
HUP0204050A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP1079764A4 (de) Behandlung sexueller störungen bei bestimmten patientengruppen
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070127